Presentation 1_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.pptx by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Table 1_WTAP modulates macrophage polarization in rheumatoid arthritis by targeting exosomal circ-CBLB via m6A modification.docx by Dawei Yan (193244)

“…Screening of m⁶A modification-related enzymes combined with RNA pull-down and RIP-qPCR assays exhibited that WTAP protein directly bound to circ-CBLB and accelerated circ-CBLB degradation by enhancing its m⁶A modification levels. Functional experiments demonstrated that WTAP overexpression decreased exosomal circ-CBLB levels and promoted macrophage polarization toward the pro-inflammatory M1 phenotype, which was reversed by m⁶A modification site mutation.…”

Image 2_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.jpeg by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Image 1_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.tif by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Image 4_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.jpeg by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Image 5_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.tif by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Image 6_Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway.jpeg by Chenchao Zou (22768010)

“…</p>Results<p>GA treatment decreased PTGS2, lactate dehydrogenase, malondialdehyde, ferrous iron, ROS, and oxidized glutathione disulfide (GSSG) levels and increased cell viability, glutathione (GSH) levels, the GSH/GSSG ratio, and GPX4 protein levels in the injury models. …”

Point Application Therapy Targeting Feishu, Pishu and Shenshu Attenuates Asthma by Suppressing Autophagy and the AMPK-mTOR Signalling Pathway by Yutong Jin (2873837)

“…The treatment additionally decreased expression levels of mTOR, LC3, NF-κB and TGF-β1 while increasing AMPK content. …”

Table 2_Neonatal supplementation of oleamide during suckling ameliorates maternal postpartum sleep interruption-induced neural impairment and endocannabinoid dysfunction in early a... by Linxi Qian (555385)

“…Introduction<p>Postpartum sleep disturbances in women are common and can significantly affect maternal mental health and breastfeeding. …”

The expression of PAX7 and MYOD1 correlate with differential expression of diverse chemokines in HuMuSC. by Katharine Striedinger (15503387)

“…Using linear regression PAX7 slope varies significantly p = 0.0001 and MYOD1 slope also varies significantly p = 0.05 n = 3 <b>(b)</b> Heat map displaying the expression levels of all cytokine protein detected in HuMuSC from collection as they activate progressively at day 0, day 3 and day 6 <i>in vitro</i>, using the high throughput proteomic Multiplex assay. …”

Table 1_Engineered miR-214 enriched Schwann cell-derived extracellular vesicles amplify therapeutic efficacy for peripheral neuropathy in T2D mice.docx by Lei Wang (6656)

“…Quantitative RT-PCR and Western blot analyses of sciatic nerve tissues showed that, compared to naïve-EVs, 214-EVs significantly increased miR-214 levels and downregulated axonal inhibitory protein PTEN and the myelination inhibitory protein cJUN. …”

<b>Chemical components, emission dynamics, and external immune functions of red palm weevil larval volatiles in response to changes in developmental stages and pathogen stress</b> by Can-Hui Ding (22140753)

“…Furthermore, pathogen stress induced distinct volatile profiles: phenylacetaldehyde unidirectionally decreased, whereas <i>n</i>-nonanol, 4-ethylguaiacol, 2-phenylethanol, hexanal, and benzophenone levels increased. …”

Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Data Sheet 5_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

“…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”

Data Sheet 3_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

“…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”